Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health
problem. The prevalence of AD is growing dramatically, especially in low‐and middle …

Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that
has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In …

Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that
has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In …

Dementia is the result of various cerebral disorders, leading to an acquired loss of memory
and impaired cognitive ability. The most common forms are Alzheimer´ s disease (AD) and …

Objective: The aim of this study was to provide a systematic and quantitative summary of
benefit and risk of Cerebrolysin in patients with mild-to-moderate Alzheimer's disease (AD) …

Cerebrolysin is a neuropeptide preparation mimicking the action of endogenous
neurotrophic factors. Positive effects of Cerebrolysin on β-amyloid-and tau-related …

Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of
neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in …

Cerebrolysin therapy has the potential to significantly aid in the treatment of a wide variety of
debilitating neurological diseases including ischemic strokes, neurodegenerative disorders …

To determine the therapeutic effect of nootropic agent Cerebrolysin on patients with mild to
moderate Alzheimer's disease (AD), we searched the Cochrane Library, Medline, PubMed …

OBJECTIVE: To assess the efficacy and safety of Cerebrolysin over 4 weeks in patients with
probable Alzheimer's disease (AD). DESIGN: A 4‐week randomized, double‐blind, placebo …